At a glance
(thousands of €, if not stated otherwise) |
Year ended |
Year ended |
Year ended |
||||||
|---|---|---|---|---|---|---|---|---|---|
Income statement(*) |
|
|
|
||||||
Product net sales |
14,753 |
2 |
- |
||||||
Collaboration revenues |
470,093 |
478,051 |
834,901 |
||||||
Cost of sales |
(1,629) |
- |
- |
||||||
R&D expenditure |
(491,707) |
(523,667) |
(420,090) |
||||||
S, G&A expenses |
(210,855) |
(185,225) |
(96,959) |
||||||
Other operating income |
53,749 |
52,207 |
50,896 |
||||||
Operating profit/loss (-) |
(165,596) |
(178,632) |
368,748 |
||||||
Net financial results |
42,598 |
(131,143) |
(220,223) |
||||||
Taxes |
(2,423) |
(1,226) |
165 |
||||||
Net profit/loss (-) from continuing operations |
(125,422) |
(311,001) |
148,689 |
||||||
Net profit from discontinued operations, net of tax |
22,191 |
5,565 |
1,156 |
||||||
Net profit/loss (-) |
(103,231) |
(305,436) |
149,845 |
||||||
|
|
|
|
||||||
Balance sheet |
|
|
|
||||||
Cash and cash equivalents |
2,233,368 |
2,135,187 |
1,861,616 |
||||||
Current financial investments |
2,469,809 |
3,026,278 |
3,919,216 |
||||||
R&D incentives receivables |
144,013 |
135,728 |
115,356 |
||||||
Assets |
5,193,160 |
5,717,731 |
6,068,609 |
||||||
Shareholders' equity |
2,643,362 |
2,670,355 |
2,875,658 |
||||||
Deferred income |
2,364,701 |
2,809,133 |
3,000,646 |
||||||
Other liabilities |
185,097 |
238,242 |
192,305 |
||||||
Cash flow |
|
|
|
||||||
Operational cash flow/operational |
(564,840) |
(517,404) |
3,162,809 |
||||||
Cash flow generated from/used in (-) operating activities |
(503,827) |
(427,336) |
3,208,617 |
||||||
Cash flow generated from/used in (-) investing activities |
541,238 |
757,288 |
(3,764,660) |
||||||
Cash flow generated from/used in (-) financing activities |
(3,876) |
22,040 |
1,335,751 |
||||||
Increase in cash and cash equivalents |
33,535 |
351,994 |
779,708 |
||||||
Transfer to current financial investments |
- |
- |
(198,922) |
||||||
Effect of currency exchange rate fluctuation on cash and cash equivalents |
56,763 |
(70,539) |
(9,966) |
||||||
Cash and cash equivalents on 31 December |
2,233,368 |
2,143,071 |
1,861,616 |
||||||
|
|
|
|
||||||
Cash and cash equivalents from continuing operations |
2,233,368 |
2,135,187 |
1,861,616 |
||||||
Cash and cash equivalents classified as assets held for sale |
- |
7,884 |
- |
||||||
Current financial investments on 31 December |
2,469,809 |
3,026,278 |
3,919,216 |
||||||
Total current financial investments and cash and cash equivalents on 31 December |
4,703,177 |
5,169,349 |
5,780,832 |
||||||
|
|
|
|
||||||
Financial ratios |
|
|
|
||||||
Number of shares issued on 31 December |
65,552,721 |
65,411,767 |
64,666,802 |
||||||
Basic income/loss (-) per share (in €) |
(1.58) |
(4.69) |
2.60 |
||||||
Diluted income/loss (-) per share (in €) |
(1.58) |
(4.69) |
2.49 |
||||||
Share price on 31 December (in €) |
49.22 |
80.48 |
186.50 |
||||||
Total group employees on 31 December |
1,309 |
1,489 |
1,003 |
||||||
|
|||||||||
Employees per site
Number of employees Galapagos group
